Literature DB >> 33712559

Autophagy, an accomplice or antagonist of drug resistance in HCC?

Yafei Wu1, Jigang Zhang1, Qin Li2.   

Abstract

Hepatocellular carcinoma (HCC) is a highly lethal malignancy characterized by poor prognosis and a low 5-year survival rate. Drug treatment is proving to be effective in anti-HCC. However, only a small number of HCC patients exhibit sensitive responses, and drug resistance occurs frequently in advanced patients. Autophagy, an evolutionary process responsible for the degradation of cellular substances, is closely associated with the acquisition and maintenance of drug resistance for HCC. This review focuses on autophagic proteins and explores the intricate relationship between autophagy and cancer stem cells, tumor-derived exosomes, and noncoding RNA. Clinical trials involved in autophagy inhibition combined with anticancer drugs are also concerned.

Entities:  

Year:  2021        PMID： 33712559      PMCID： PMC7954824          DOI： 10.1038/s41419-021-03553-7

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  137 in total

1.  Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy.

Authors:  Yoshinobu Ichimura; Satoshi Waguri; Yu-Shin Sou; Shun Kageyama; Jun Hasegawa; Ryosuke Ishimura; Tetsuya Saito; Yinjie Yang; Tsuguka Kouno; Toshiaki Fukutomi; Takayuki Hoshii; Atsushi Hirao; Kenji Takagi; Tsunehiro Mizushima; Hozumi Motohashi; Myung-Shik Lee; Tamotsu Yoshimori; Keiji Tanaka; Masayuki Yamamoto; Masaaki Komatsu
Journal:  Mol Cell       Date:  2013-09-05       Impact factor: 17.970

2.  Phosphorylation of Bcl-2 plays an important role in glycochenodeoxycholate-induced survival and chemoresistance in HCC.

Authors:  Maojun Zhou; Qi Zhang; Jinfeng Zhao; Mingmei Liao; Sailan Wen; Manyi Yang
Journal:  Oncol Rep       Date:  2017-07-18       Impact factor: 3.906

3.  Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update.

Authors:  Angela Gauthier; Mitchell Ho
Journal:  Hepatol Res       Date:  2012-11-12       Impact factor: 4.288

Review 4.  Nrf2-p62 autophagy pathway and its response to oxidative stress in hepatocellular carcinoma.

Authors:  Desirée Bartolini; Katiuscia Dallaglio; Pierangelo Torquato; Marta Piroddi; Francesco Galli
Journal:  Transl Res       Date:  2017-11-29       Impact factor: 7.012

5.  Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.

Authors:  Satoshi Shimizu; Tetsuo Takehara; Hayato Hikita; Takahiro Kodama; Hinako Tsunematsu; Takuya Miyagi; Atsushi Hosui; Hisashi Ishida; Tomohide Tatsumi; Tatsuya Kanto; Naoki Hiramatsu; Naonobu Fujita; Tamotsu Yoshimori; Norio Hayashi
Journal:  Int J Cancer       Date:  2011-09-12       Impact factor: 7.396

Review 6.  The role of microRNA in the resistance to treatment of hepatocellular carcinoma.

Authors:  Muhammad Yogi Pratama; Devis Pascut; Muhammad Nasrum Massi; Claudio Tiribelli
Journal:  Ann Transl Med       Date:  2019-10

7.  LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells.

Authors:  H Xiong; Z Ni; J He; S Jiang; X Li; J He; W Gong; L Zheng; S Chen; B Li; N Zhang; X Lyu; G Huang; B Chen; Y Zhang; F He
Journal:  Oncogene       Date:  2017-02-06       Impact factor: 9.867

8.  Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells.

Authors:  Xiaofang Sun; Zhanhui Ou; Ruochan Chen; Xiaohua Niu; De Chen; Rui Kang; Daolin Tang
Journal:  Hepatology       Date:  2015-11-26       Impact factor: 17.425

9.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy.

Authors:  Carolina Simioni; Alberto M Martelli; Alice Cani; Rengul Cetin-Atalay; James A McCubrey; Silvano Capitani; Luca M Neri
Journal:  Oncotarget       Date:  2013-09
View more
  3 in total

1.  Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib.

Authors:  Flavia Fondevila; Carolina Méndez-Blanco; Paula Fernández-Palanca; Tania Payo-Serafín; Jos van Pelt; Chris Verslype; Javier González-Gallego; José L Mauriz
Journal:  Int J Mol Sci       Date:  2021-10-29       Impact factor: 5.923

2.  HBx increases chromatin accessibility and ETV4 expression to regulate dishevelled-2 and promote HCC progression.

Authors:  Chuqian Zheng; Min Liu; Yanping Ge; Yanyan Qian; Hong Fan
Journal:  Cell Death Dis       Date:  2022-02-04       Impact factor: 8.469

Review 3.  CAM-DR: Mechanisms, Roles and Clinical Application in Tumors.

Authors:  Yuejiao Huang; Yuchan Wang; Jie Tang; Shiyi Qin; Xianjuan Shen; Song He; Shaoqing Ju
Journal:  Front Cell Dev Biol       Date:  2021-07-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.